Thank you so much, Gunilla. Next slide please. So our R&D portfolio continues to advance, as Gunilla has described. And this is really built on two complementary platforms: the antibodies and the BrainTransporter platform. A balanced mix of funded partnerships with Eisai, BMS, Novartis, and Eli Lilly, together with proprietary programs, provides both external validation and significant long-term value creation opportunities in the portfolio. All BrainTransporter collaborations are progressing well, and during the quarter, we have further strengthened the platform through two new collaborations: the Eli Lilly partnership, which represents a major validation by a leading neuroscience company and highlights the platform's broad potential in the CNS. And then we have the Mesenkia collaboration that marks our first step into oncology, expanding the BrainTransporter platform beyond neurodegenerative diseases and broadening its future application potential. So overall, we continue to advance the diverse, increasingly partnered, validated pipeline with expanding scientific and commercial potential, both for our antibody and our BrainTransporter platform. Next slide please. So, taking a closer look at our alpha-synuclein portfolio, it is moving forward and expanding. So for Exidavnemab during the quarter, we have evaluated the safety data from the phase two AXIS study of Exidavnemab in both Parkinson's disease and Multiple System Atrophy. The results confirmed a favorable safety profile of the antibody, which is an important milestone for the program. This data will provide a strong foundation for the next step of development, and we are currently planning for phase 2B studies in both Multiple System Atrophy and Parkinson's disease-related dementia, with the ambition to initiate these studies next year. Exidavnemab remains the most advanced alpha-synuclein-targeting program in our pipeline and addresses a significant unmet medical need in neurodegenerative diseases. And for BAN2238, our BrainTransporter-enabled alpha-synuclein antibody. We continue to make progress with the IND-enabling activities during the quarter for BAN2238. It combines our disease expertise in alpha-synuclein biology with the BrainTransporter technology, which is designed to enhance the antibody's delivery across the blood-brain barrier. And this program is progressing according to plan, and we are currently expecting to initiate clinical development next year. So together, Exidavnemab and BAN2238 represent a complementary strategy combining the most advanced clinical stage asset with a next-generation BrainTransporter-enabling program targeting the same underlying disease biology. So next slide, please.
So, one of the quarter's key highlights for us was really the new BrainTransporter collaboration with Eli Lilly.
Lilly's selection of the BrainTransporter for next-generation CNS therapies provides a strong validation from a leading pharmaceutical company and reinforces the importance of efficient blood-brain delivery for CNS drug development. And this collaboration, of course, expands the potential application of the BrainTransporter beyond our internal programs. And it combines BioArctic's neuroscience expertise with Eli Lilly's global development capabilities, further strengthening the platform for long-term strategic and commercial value. The Mesenkia collaboration in oncology marks BioArctic's entry into the oncology target space and expands the application of the BrainTransporter beyond neurodegenerative diseases.
And the main focus here is glioblastoma, which is a highly aggressive brain cancer with significant unmet medical need. And together with Mesenkia, we are now evaluating a novel approach by combining the BrainTransporter with Mesenkia's HVEM-targeting antibody, enhancing drug delivery to the brain and the capability to reach tumor cells associated with recurrence and treatment resistance. The initial goal is to generate a drug candidate and establish a preclinical proof of concept for the program, further demonstrating the versatility of the BrainTransporter platform. So taken together, the Eli Lilly and Mesenkia collaborations highlight the broad potential of the BrainTransporter. Lilly validates the platform in neurodegeneration, while Mesenkia extends. Extends its application into oncology, demonstrating its versatility across multiple disease areas.
So, next slide, please. And then I will hand over to our Chief Commercial Officer, Anna-Kaija Grönblad. Sorry. Thank you, Johanna. So let me go back to Leqembi and the global rollout of the subcutaneous treatment, as I already mentioned. This is clearly an important step in expanding patient access and further strengthening our continued growth. So in the US, the FDA approval came in July for the Leqembi Iqlik initiation treatment. It is available as of this week. This will clearly increase momentum as we move into the second half of 2026. And this will allow people the option to inject the drug themselves instead of going to the hospitals. So they can do this at home for the whole course of treatment. And so, without having to come to the clinic for the time-consuming and more invasive infusions. This change is really expected to broaden uptake, especially for people who live far from the clinics or travel frequently. Looking at other benchmarks in the industry, we believe the uptake in the US will happen gradually as the coverage will broaden at different time points, with an expected shift potentially coming in the beginning of 2027. And we hope that the Medicare Part D coverage for both the initiation and maintenance can begin in January 2027. But we believe it will clearly be a commercial game changer and an advantage versus the competition in Japan. We expect the approval soon in this third quarter of 2026 and reimbursement a bit later, expected to follow in the fourth quarter. And in China. The product is currently under priority review, and we expect the approval in the first half of 2027. Importantly, data presented in July this summer at the AAIC Congress in London showed that the efficacy and the safety of the subcutaneous administration are comparable to the IV treatment. So it clearly supports the potential of this more convenient treatment option. Eisai also continues to make progress across other international markets. So during the second quarter, Leqembi was launched in Australia, Belgium, Brazil and India. And at the same time, market interest is unfortunately generally slower in Europe. The process continues to improve patient access across Europe. Here, the less frequent IV maintenance dosing is currently under EMA regulatory review, and if approved, this could not only enhance the convenience of continuous treatment but also facilitate access discussions in some other countries in Europe. In the UK, commercial discussions between Eisai and the NHS England are ongoing, and we are seeing some encouraging interest from several private clinics in the Nordic countries. And as we progress, we are also continuing discussions for broader public reimbursement. So overall, we are very pleased with the progress, and together with the uptake and usage of blood-based biomarkers, we see significant opportunities to further expand patient access and growth.
If you go to the next slide. So coming back to the AD Congress in London this summer. Several speakers showed data on how the drug is performing in the real world. Here I am highlighting a US post-market study called LEADER, which now includes 16 clinical sites across the country. Data were presented for about 400 patients from 13 sites, and after an average of 17 months of Leqembi use, approximately 83% had not progressed to more advanced disease as assessed by a clinician. So of these, 76% remained at the same disease stage and 6.5% improved for a bit more than 200 people who have reached two years of treatment. The data are similar, 74% were stable and 9% improved. Among the more than 200 patients that had been on treatment for more than 18 months, almost 80% transitioned to maintenance treatment either with Leqembi IV or subcutaneous Leqembi. So finally, safety observations in this real-world study were consistent with the FDA-approved label. We are looking forward to the next data cut. Approximately 600 patients will likely be presented in November at the CTAD Congress.
So with that, I hand over to Anders, our CFO.